EPZM earnings call for the period ending June 30, 2020.
News & Analysis: Epizyme
Investors were looking forward to the drug company's transition to commercial operations, but the coronavirus pandemic could delay the maturation process.
The pharma company released full-year 2019 operating results.
The biotech's FDA approval was priced in, but the company still has potential.
The company put a clinical hold from 2018 behind it and submitted its first-ever new drug application.
A new update on its epigenetics drug, tazemetostat, has kindled investor optimism.
The biotech reported new data for tazemetostat in lymphoma at a key industry conference.
The biotech has won additional fast-track designations for its lead drug, tazemetostat.